Trial Profile
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Dasotraline (Primary)
- Indications Binge-eating disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 25 Jul 2018 Primary endpoint of change from baseline in number of binge days in the group treated with dasotraline 4 mg/day versus the placebo-treated group has not been met, according to Sunovion Pharmaceuticals media release.
- 25 Jul 2018 Primary endpoint of Change from baseline in number of binge days in the group treated with dasotraline 6 mg/day versus the placebo-treated group has been met, according to Sunovion Pharmaceuticals media release.
- 01 Jul 2018 Status changed from active, no longer recruiting to completed.